Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Mereo BioPharma
Biotech
Zydus’ Sentynl pens $475M deal for Mereo's rare lung disease drug
Sentynl has penned a deal potentially worth $475 million for the option to market Mereo's phase 3-ready genetic respiratory disease drug in the U.S.
Marissa Russo
Aug 11, 2026 10:20am
Amgen weaves in UK biotech with up to $840M acquisition
Jan 6, 2026 10:35am
Ultragenyx plans cost-cutting push after flunking phase 3 trials
Jan 2, 2026 5:37am
Lack of early win for Ultragenyx’s bone disorder med dents stock
Jul 10, 2025 8:04am
Ultragenyx, Mereo's brittle bone drug sustains fracture rate cut
Jun 12, 2024 8:55am
Ultragenyx, Mereo's bone disease med cuts fractures by 67%
Oct 16, 2023 12:39pm
